Dr. David Warren reports

ADAPTOGENICS APPOINTS ANTOUN NABHAN AS PRESIDENT

Adaptogenics Health Corp. has appointed Antoun Nabhan, JD, as president, effective Oct. 1, 2026.

Mr. Nabhan brings nearly two decades of health care investment, corporate finance and business development experience. He has led or advised on more than $2-billion in buy-side health care transactions involving multiple assets that subsequently received regulatory approval, including Kyprolis, Stivarga, Quinsair and Somryst.

Mr. Nabhan previously served as senior vice-president at Oaktree Capital Management LP and currently manages a portfolio of publicly traded health care equities at Sagamore Bioventures, bringing institutional investment experience to the company's leadership team. His operating roles include chief financial officer of Establishment Labs, and vice-president of corporate development at Pear Therapeutics, Raptor Pharmaceuticals and Capnia Inc., now Soleno Therapeutics. His background spans pharmaceutical assets, medical devices and prescription digital therapeutics.

Across his roles at Establishment Labs and Soleno Therapeutics, formerly Capnia, Mr. Nabhan led two Nasdaq Stock Market initial public offering processes. He also held transactional executive roles at Onyx Pharmaceuticals before its acquisition by Amgen and Raptor Pharmaceuticals before its acquisition by Horizon Pharma. He has also co-founded three pharmaceutical development companies, two of which, Convivia and Incellico, have been acquired.

Mr. Nabhan holds a JD from Harvard Law School and an AB from the University of Chicago, where he graduated phi beta kappa.

As president, Mr. Nabhan will lead the identification, evaluation and negotiation of asset acquisitions, licensing partnerships and strategic collaborations. He will work with chief executive officer, Dr. J. David Warren, to connect scientific evaluation with transaction structure and capital planning as the company pursues proprietary peptide and small molecule opportunities.

"Antoun knows how to identify promising assets, negotiate the rights that matter and build the partnerships needed to advance them," said Dr. Warren. "His experience complements our scientific capabilities and will be important as we build a portfolio with meaningful commercial potential."

"The opportunity is to bring strong science and thoughtful dealmaking together," said Mr. Nabhan. "I look forward to working with David and this very talented team to secure differentiated assets and develop them with scientific rigour and a disciplined use of capital."

About Adaptogenics Health Corp.

Adaptogenics Health is a Canadian-based nutraceutical company focused on the formulation and distribution of functional mushroom products and nutritional supplement alternatives. The company intends to evaluate opportunities to establish a proprietary pipeline of peptide and small-molecule therapeutics focused on metabolic health, muscle preservation and inflammation. Led by an experienced scientific and business team, the company combines asset acquisition and licensing with targeted discovery and delivery research to create differentiated therapeutic candidates and defensible intellectual property. Adaptogenics also maintains its existing nutraceutical business and is evaluating complementary GLP-1 companion product opportunities

We seek Safe Harbor.